Alberta Investment Management Corp Jounce Therapeutics, Inc. Transaction History

Alberta Investment Management Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 16, 2018	SELL	$13.4 - $28.4 $381,900 - $809,400	-28,500 Closed	0 $0
Q4 2017 Feb 15, 2018	SELL	$12.52 - $17.82 $33,804 - $48,114	-2,700 Reduced 8.65%	28,500 $363,000
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $348,504 - $530,088	31,200	31,200 $486,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

Stay updated on Alberta Investment Management Corp with notifications on news.